Innovent reveals Phase 1 clinical results of Mazdutide for obesity
Category: #health  By Mateen Dalal  Date: 2022-06-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovent reveals Phase 1 clinical results of Mazdutide for obesity

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufacturers, and commercializes top-class medicines, has recently announced the outcomes of high-dose cohorts in Phase 1 clinical study of mazdutide (IBI362), a glucagon receptor dual agonist, and a glucagon-like petide-1 (GLP-1), in adults in China with obesity or overweight at ENDO 2022.

As per credible sources, this placebo-controlled, randomized, double-blind, multiple-ascending-dose study examined the tolerability, safety, and PK/PD features of mazdutide in Chinese participants with obesity or overweight. Each cohort of participants established administration for 12 weeks, except those members in cohort 4 received administration for 16 weeks.

The study's principal investigator, Professor Linong Ji from Peking University People's Hospital, stated that the obese population of China had surpassed 100 million. Most patients cannot achieve weight loss owing to the lifestyle intervention, specifying the urgent requirement for a highly effective and safe weight loss treatment.

The country is pleased to see high-dose mazdutide demonstrating a similar safety profile while showcasing more effective weight loss and several benefits in metabolic parameters.

While commenting on the outcomes, Vice President of Clinical Development of Innovent, Dr. Lei Qian said that the high dose of mazdutide demonstrated satisfactory safety, admissibility, and robust efficacy for weight loss in Chinese patients with obesity or overweight.

Mazdutide is the only molecule to accomplish a 12-week weight loss by around 11.5% among single-agent anti-obesity molecules authorized or under development.

These results showcase the dominance of glucagon receptor dual agonists and GLP-1 around GLP-1 receptor mono-agonists in terms of losing weight.

Moreover, as per the recent reports, the study also authorized the multiple metabolic assistances offered by mazdutide to patients with obesity or overweight. The firm is also planning to continue developing the high-dose mazdutide in obesity and overweight and other potential indications apart from the different exciting results.

Source Credit - https://www.prnewswire.com/news-releases/innovent-releases-results-of-high-dose-cohorts-in-phase-1-clinical-study-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-at-endo-2022-301566184.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...